AppLovin (APP) stock falls 3% premarket. Oppenheimer cuts target to $660, Wedbush holds $640. Both maintain Outperform ratings on e-commerce expansion. The postAppLovin (APP) stock falls 3% premarket. Oppenheimer cuts target to $660, Wedbush holds $640. Both maintain Outperform ratings on e-commerce expansion. The post

AppLovin (APP) Stock Dips in Premarket Despite Bullish Analyst Outlook

2026/03/06 22:51
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Key Takeaways

  • Oppenheimer maintains Outperform rating on AppLovin while reducing price target from $740 to $660
  • Wedbush maintains Outperform rating with $640 price target unchanged
  • Analysts remain optimistic about AXON 2.0 platform expansion into non-gaming sectors
  • Company launching AI-powered video advertisements and dynamic product catalogs for e-commerce
  • APP shares down approximately 28% year-to-date with ~3% premarket decline Friday

Two major Wall Street investment firms weighed in on AppLovin this week, maintaining their bullish positions despite the company’s challenging start to 2026. The stock has declined more than 28% since the year began and experienced an additional 3% drop in Friday’s premarket session.


APP Stock Card
AppLovin Corporation, APP

Oppenheimer reduced its price objective to $660 from a previous $740 while maintaining its Outperform rating. The investment firm cited the expansion potential of AXON 2.0 beyond the gaming sector as the primary reason for its continued optimism.

The firm identified several near-term growth drivers including innovative campaign formats, AI-powered creative tools, and initiatives in lead generation. The anticipated full launch of AXON 2.0 was emphasized as a significant catalyst for demand.

Wedbush’s analyst Alicia Reese and her team maintained their $640 price objective alongside an Outperform rating. The firm conducted a detailed discussion with AppLovin management covering their technology development strategy, e-commerce growth plans, and competitive positioning.

E-Commerce Expansion in Full Swing

According to Wedbush’s analysis, the company’s primary near-term objective involves rapidly scaling AppLovin’s self-service e-commerce platform. This initiative features 30-60 second video advertisements powered by artificial intelligence alongside dynamic product catalog functionality.

The analysts expect the core gaming segment to maintain growth rates between 20% and 30%, providing what Wedbush characterizes as a solid foundation for broader expansion efforts.

Market Competition Analysis

Regarding competitive dynamics, Wedbush observed that many of AppLovin’s primary competitors simultaneously serve as partners. In probabilistic bidding scenarios — characterized by limited user identity information — AppLovin maintains dominance, especially within mobile gaming advertising.

The analysts highlighted that rivals lack AppLovin’s sophisticated purchasing tools, resulting in diminished lifetime value for advertisers and ultimately driving them toward AppLovin’s platform. While smaller advertising technology companies can operate in this space, they face significant challenges in capturing meaningful market share.

From a capital allocation perspective, Wedbush noted AppLovin’s robust cash flow generation and indicated that share repurchases will remain the top priority given the stock’s current trading levels relative to their fair value assessment.

AppLovin currently commands a market capitalization of approximately $148 billion, with average daily trading volume around 5.7 million shares.

The post AppLovin (APP) Stock Dips in Premarket Despite Bullish Analyst Outlook appeared first on Blockonomi.

Market Opportunity
Bullish Degen Logo
Bullish Degen Price(BULLISH)
$0.003653
$0.003653$0.003653
-0.16%
USD
Bullish Degen (BULLISH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09